The COVID-19 pandemic has forced companies to adapt in unprecedented ways. More than ever, learning agility – the desire, capability, and skillset that allow people to navigate change and uncertainty – has become critical to organizational success and can lead to new opportunities.
In this episode, Syneos Health® experts, Karen White, Vice President of Human Resources and Kiely Flanigan, Director of Global Medical Affairs from our consulting team, discuss why learning agility matters and how it can add value to business areas across the pharmaceutical industry, from global drug launches to the increasing number of rare disease therapies.
For a deeper dive into our perspective on how businesses have adapted during COVID-19, read this report. Be sure to check out our recent article on learning agility and listen to the rest of our Medical Affairs podcast series episodes:
If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.
Like what you’re hearing? Be sure to rate and review us!
We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected].